Journals / Glokom Katarakt / 2012 / Cilt: 7 - Sayı: 2

Risk factors for encapsulated blebs following trabeculectomy

Trabekülektomi sonrası enkapsüle bleb gelişimi ile ilişkili faktörler

Pages
95–100
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Increased preoperative antiglaucoma medication use and prevalence of preoperative alpha mimetic use were associated with EB development following trabeculectomy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the incidence and risk factors for the development of encapsulated bleb (EB) following trabeculectomy.
📊
Key Findings & Data:Materials and Methods: Records of patients who underwent trabeculectomy between July 2009 and January 2011 and who were followed-up for at least 3 months were investigated.
💡
Conclusion & Impact:Conclusion: Increased preoperative antiglaucoma medication use and prevalence of preoperative alpha mimetic use were associated with EB development following trabeculectomy.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the incidence and risk factors for the development of encapsulated bleb (EB) following trabeculectomy. Materials and Methods: Records of patients who underwent trabeculectomy between July 2009 and January 2011 and who were followed-up for at least 3 months were investigated. Juvenile glaucoma, secondary glaucoma such as neovascular glaucoma, uveitic glaucoma, and combined surgeries were excluded. Ninety-eight eyes of 90 consecutive patients were included. Age, sex, systemic disease, glaucoma type, visual acuity (VA), preoperative intraocular pressure (IOP), preoperative antiglaucoma medications, history of intraocular surgery and laser, intraoperative mitomycin-C (MMC) use, type of conjunctival flap postoperative IOP, and postoperative number of glaucoma medications were recorded. A localized, elevated, tense, dome-shaped bleb with prominent surface vessels was accepted as EB. Two groups of eyes with or without EB were compared. Results: EB was detected in 21 of 98 eyes (21.4%) following trabeculectomy. The mean follow-up time was 8.3±5.4 months. There were no difference in terms of age, sex, glaucoma type, preoperative IOP, or preoperative VA between the groups (p>0.05). Mean number of preoperative antiglaucomatous medications was 3.76±0.54 in group 1 and 3.45±0.65 in group 2 (p=0.04). There was no significant difference between the groups in use of preoperative antiglaucomatous drugs such as carbonic anhydrase inhibitors, &#946; blockers, and prostaglandin analogs; however, increased prevalence of preoperative alpha mimetic use was detected in group 1 (p<0.05). EB was detected in 13 of 62 eyes that underwent the limbal-based conjunctival flap technique, in 8 of 36 eyes that underwent the fornix-based conjunctival flap technique, in 14 of 63 eyes that underwent trabeculectomy with intraoperative application of MMC, and in 7 of 35 eyes that underwent trabeculectomy without MMC (p>0.05 for each). Conclusion: Increased preoperative antiglaucoma medication use and prevalence of preoperative alpha mimetic use were associated with EB development following trabeculectomy.

Özet

Amaç: Trabekülektomi ameliyatı sonrasında enkapsüle bleb (EB) sıklığını ve gelişimi ile ilişkili faktörleri incelemek. Gereç ve Yöntemler: Temmuz 2009-Ocak 2011 arasında trabekülektomi yapılmış ve en az 3 ay takibi olan hastaların dosyaları geriye dönük olarak incelendi. Gelişimsel glokom; neovasküler glokom, uveitik glokom gibi sekonder glokomu olanlar, kombine cerrahiler çalışma dışı bırakıldı. Çalışmaya ardışık 90 hastanın 98 gözü dahil edildi. Hastaların yaşı, cinsi, sistemik hastalığı, glokom tipi, görme keskinlikleri (GK), ameliyat öncesi GİB, ameliyat öncesi kullanılan glokom ilaçları, geçirilmiş göz içi cerrahi veya lazer; ameliyat sırasında Mitomisin-C (MMC) kullanımı, konjonktival fleb tipi, ameliyat sonrası GİB ve ameliyat sonrası ilaç sayıları kaydedildi. Biyomikroskopide lokalize, kabarık, yüzeyinde belirgin damarlanma olan ve duvarlarında kalınlaşma izlenen blebler EB olarak değerlendirildi ve EB gelişen olgular grup 1, gelişmeyen olgular grup 2 olarak sınıflandırıldı. Bulgular: Filtran cerrahi geçiren 98 gözün 21 (%21.4)'inde EB geliştiği saptandı. Ortalama takip süresi 8.3±5.4 aydı. Yaş, cins, glokom tipi, ameliyat öncesi GİB, ameliyat öncesi GK açısından gruplar arasında fark bulunmadı (p>0.05). Ameliyat öncesi kullanılan ortalama antiglokomatöz ilaç sayısı grup 1'de 3.76±0.54 iken; grup 2'de 3.45±0.65 idi (p=0.04). Ameliyat öncesi kullanılan ilaçlar karşılaştırıldığında karbonik anhidraz inhibitörü, β bloker ve prostaglandin kullanımı açısından anlamlı fark görülmezken, ameliyat öncesi alfa mimetik kullananlarda EB gelişiminin daha fazla olduğu saptandı (p<0.05). Limbus tabanlı konjonktival fleb tekniği kullanılan 62 gözün 13'ünde; forniks tabanlı fleb tekniği kullanılan 36 gözün 8'inde; intraoperatif MMC kullanılan 63 gözün 14'ünde, MMC kullanılmayan 35 gözün 7'sinde EB geliştiği görüldü (p=0.05). Sonuç: Ameliyat öncesi kullanılan glokom ilacı sayısının artması ve ameliyat öncesi alfa mimetik damla kullanımı ile trabekülektomi cerrahisi sonrası EB gelişimi riski artmaktadır.

🔖

Cite This Article

ALTAN, Ç., ŞATANA, B., BAZ, Ö., BAŞARIR, B., PAŞAOĞLU, I., KÜÇÜKSÜMER, Y., DEMİROK, A. (2012). Risk factors for encapsulated blebs following trabeculectomy. Glokom Katarakt, Cilt: 7 - Sayı: 2, 95–100. https://ajindex.com/articles/216183

References (17)

  1. Schwartz AL, Van Veldhuisen PC, Gaasterland DE, et al. The Advanced Glaucoma Intervention Study (AGIS): 5. Encap sulated bleb after initial trabeculectomy. Am J Ophthalmol 1999;127:8-19
  2. Yarangümeli A, Köz OG, Kural G. Encapsulated blebs fol lowing primary standard trabeculectomy: course and treat ment. J Glaucoma 2004;13:251-5
  3. Oh Y, Katz LJ, Spaeth GL, et al. Risk factors for the develop ment of encapsulated filtering blebs. The role of surgical glove powder and 5-fluorouracil. Ophthalmology 1994;101:629-34
  4. Feldman RM, Gross RL, Spaeth GL, et al. Risk factors for the development of Tenon’s capsule cysts after trabeculectomy. Ophthalmology 1989;96:336-41
  5. Azuara-Blanco A, Bond JB, Wilson RP, et al. Encapsulated filtering blebs after trabeculectomy with mitomycin-C. Oph thalmic Surg Lasers 1997;28:805-9
  6. Richter CU, Shingleton BJ, Bellows AR, et al. The deve lopment of encapsulated filtering blebs. Ophthalmology 1988;95:1163-8
  7. Mandal AK. Results of medical management and mitomycin C-augmented excisional bleb revision for encapsulated filte ring blebs. Ophthalmic Surg Lasers 1999;30:276-84
  8. Scott DR, Quigley HA. Medical management of a high bleb pha se after trabeculectomies. Ophthalmology 1988;95:1169-73
  9. Campagna JA, Munden PM, Alward WL. Tenon’s cyst forma tion after trabeculectomy with mitomycin C. Ophthalmic Surg 1995;26:57-60
  10. Yarangümeli A, Elhan AH, Köz AG, ve ark. Trabekülektomi: 304 Ameliyatda sonuçlar ve komplikasyonlar. MN-Oftalmol 2002;9:162-7
  11. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795-8 12. Van Buskirk EM. Cysts of Tenon’s capsule following filtration surgery. Am J Ophthalmol 1982;94:522-7
  12. Sherwood MB, Spaeth GL, Simmons ST, et al. Cysts of Tenon’s capsule following filtration surgery. Medical manage ment. Arch Ophthalmol 1987;105:1517-21
  13. Ophir A. Encapsulated filtering bleb. A selective review-new deductions. Eye 1992;6:348-52
  14. Ophir A, Ticho U. Encapsulated filtering bleb and subconjunc tival 5-fluorouracil. Ophthalmic Surg 1992;23:339-41
  15. Skuta GL, Beeson CC, Higginbotham EJ, et al. Intraoperati ve mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology 1992;99:438-44
  16. Ophir A, Ticho U. A randomized study of trabeculectomy and subconjunctival administration of fluorouracil in primary gla ucomas. Arch Ophthalmol 1992;110:1072-5
  17. Ruderman